Latest Commercial Readiness News

IperionX rebuffs short seller claims by highlighting robust US government support and accelerating titanium production scale-up in Virginia. The company secures over $59 million in funding and advances critical minerals projects toward commercial readiness.

Optiscan Imaging has entered a three-year strategic collaboration with Australian Clinical Labs to validate and deploy its InForm™ digital pathology platform, aiming to transform diagnostic workflows with real-time tissue analysis.

Tryptamine Therapeutics has raised $6.1 million to fast-track clinical development of its IV-infused psilocin drug TRP-8803, targeting binge eating disorder and other neuropsychiatric conditions.

Global Uranium and Snow Lake Resources have agreed to merge, creating a leading US-focused uranium developer with a diversified project portfolio. The announcement also highlights a maiden high-grade resource at Maybell and ongoing promising drilling at Pine Ridge.

Memphasys has sharpened its commercial focus on the Felix™ System, securing a major distribution expansion in the MENA region and cutting operational costs by 40%, setting the stage for a global market push.

Lithium Universe Limited has secured exclusive rights to a breakthrough silver extraction technology from Macquarie University, promising high-purity silver recovery from solar panels while preserving valuable silicon wafers. This innovation complements their existing recycling and lithium refining strategies in North America.

Locksley Resources appoints Kerrie Matthews as Managing Director and CEO to spearhead the commercialisation of U.S.-produced antimony, following a landmark domestic metal ingot milestone.

Rhythm Biosciences reports strong Q1 FY26 progress, securing strategic partnerships and advancing commercial readiness for its ColoSTAT® colorectal cancer test alongside robust growth in its geneType platform.

LTR Pharma has made significant strides towards its US market debut with ROXUS, bolstered by expert appointments and peer-reviewed clinical data validating its rapid-onset ED treatments.

Anteris Technologies Global Corp. has raised A$38.5 million in a private placement to accelerate the global commercialization and pivotal clinical trial of its innovative DurAVR® transcatheter aortic valve replacement device.

EMVision Medical Devices has expanded its pivotal clinical trial sites, secured a $3 million government grant, and raised $14 million through placement and share purchase plan, positioning itself strongly for upcoming regulatory submissions and commercialisation.

Sprintex has successfully delivered and begun commissioning integrated control systems for Mest Water’s Netherlands facility, marking a key milestone before commercial production scale-up and a potential €9.3 million maiden order.